Nektar Therapeutics | NKTR - Assets


Nektar Therapeutics reported $280.41M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Agios Pharmaceuticals USD 1.18B 112.24M Mar/2026
ALKERMES USD 4.26B 1.77B Mar/2026
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
Amgen USD 92.5B 1.92B Mar/2026
Baxter International USD 19.85B 209M Mar/2026
BioCryst Pharmaceuticals USD 465.05M 49.11M Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Cara Therapeutics USD 32.07M 6.95M Dec/2025
Cipla INR 424.96B 23.32B Mar/2026
Dr.Reddys Laboratories INR 581.23B 18.34B Mar/2026
Eisai JPY 1.45T 37.11B Mar/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
Exelixis USD 2.59B 250.83M Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Grifols EUR 23.15B 142.7M Dec/2025
Halozyme Therapeutics USD 2.67B 147.4M Mar/2026
Incyte USD 7.34B 381.14M Mar/2026
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
Ironwood Pharmaceuticals USD 434.57M 37.66M Mar/2026
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
MacroGenics USD 217.87M 38.97M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Neurocrine Biosciences USD 4.91B 274.7M Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Takeda JPY 15.45T 44.34B Mar/2026
Teva Pharmaceutical Industries USD 40.04B 708M Mar/2026
Xencor USD 736.85M 138.65M Mar/2026